http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yang, Deok-Hwan,Kim, Mi-Hyun,Lee, Youn-Kyung,Hong, Cheol Yi,Lee, Hyun Ju,Nguyen-Pham, Thanh-Nhan,Bae, Soo Young,Ahn, Jae-Sook,Kim, Yeo-Kyeoung,Chung, Ik-Joo,Kim, Hyeoung-Joon,Kalinski, Pawel,Lee, Je-J Springer International 2011 Annals of hematology Vol.90 No.12
<P>For wide application of a dendritic cell (DC) vaccination in myeloma patients, easily available tumor antigens should be developed. We investigated the feasibility of cellular immunotherapy using autologous alpha-type 1-polarized dendritic cells (관DC1s) loaded with apoptotic allogeneic myeloma cells, which could generate myeloma-specific cytotoxic T lymphocytes (CTLs) against autologous myeloma cells in myeloma patients. Monocyte-derived DCs were matured by adding the 관DC1-polarizing cocktail (TNF관/IL-1관/IFN-관/IFN-관/poly-I:C) and loaded with apoptotic allogeneic CD138(+) myeloma cells from other patients with matched monoclonal immunoglobulins as a tumor antigen. There were no differences in the phenotypic expression between 관DC1s loaded with apoptotic autologous and allogeneic myeloma cells. Autologous 관DC1s effectively took up apoptotic allogeneic myeloma cells from other patients with matched subtype. Myeloma-specific CTLs against autologous target cells were successfully induced by 관DC1s loaded with allogeneic tumor antigen. The cross-presentation of apoptotic allogeneic myeloma cells to 관DC1s could generate CTL responses between myeloma patients with individual matched monoclonal immunoglobulins. There was no difference in CTL responses between 관DC1s loaded with autologous tumor antigen and allogeneic tumor antigen against targeting patient's myeloma cells. Our data indicate that autologous DCs loaded with allogeneic myeloma cells with matched immunoglobulin can generate potent myeloma-specific CTL responses against autologous myeloma cells and can be a highly feasible and effective method for cellular immunotherapy in myeloma patients.</P>
레거시 시뮬레이터를 활용한 FLIGHTLAB<SUP>®</SUP> 모델 기반의 조종성 평가 환경 설계 연구
양창덕(Chang Deok Yang),이승덕(Seung Deok Lee),조환희(Hwan Heui Cho),정동우(Dong Woo Jung) 한국항공우주학회 2016 韓國航空宇宙學會誌 Vol.44 No.6
고-신뢰도 모델을 이용한 조종성 평가 시뮬레이션 환경은 비행제어시스템의 설계/평가에 필수적으로 요구된다. 한국항공우주산업㈜에서는 소형민수헬기 핵심기술 개발과 관련하여 자동비행조종장치 소프트웨어 개발과제를 수행 중에 있으며 제어법칙 설계를 위한 비행동역학 모델 및 해석을 위해 상용 도구인 FLIGHTLAB을 이용하고 있다. 본 연구에서는 기존에 개발된 레거시 시뮬레이터를 FLIGHTLAB 모델과 연동하고 이를 조종성 평가에 활용한 내용을 다루었다. 본 논문에서는 외부 연동을 위한 FLIGHTLAB 모델의 설정, 연동프로그램 개발 및 연동 방안에 대한 내용을 수록하였다. 또한 본 논문에서는 레거시 시뮬레이터와의 연동을 통해 ADS-33E-PRF의 호버 및 pirouette MTE 기동비행을 수행하고 평가 결과를 수록하였다. The handling quality simulator including high fidelity flight mechanics model is indispensable component to design and verify the flight control system. Korea Aerospace Industries, LTD. (KAI) has been performing LCH (Light Civil Helicopter) core technology development program regarding automatic flight control system (AFCS) software development. And KAI has been developing flight mechanics model using FLIGHTLAB to design and evaluate the AFCS flight control law. This paper presents the handling quality assessment environment development results through the combining FLIGHTLAB with a legacy simulator. And this paper details the FLIGHTLAB model, application development process and FLIGHTLAB interface design. The developed handling quality assessment environment has been demonstrated with the ADS-33E hover and pirouette MTE (Mission Task Element) maneuver simulation.
Prostacyclin 분무형과 정주형이 폐동맥 고혈압에 미치는 효과
양미경,이현화,김종성,신백효,김성덕,임옥환 대한마취과학회 1998 Korean Journal of Anesthesiology Vol.35 No.3
Background: Prostacyclin administered intravenously has demonstrated intermediate pulmonary specificity and its aerosol form has an even greater pulmonary selectivity. There have been few systematic analyses of the difference in response according to the route of administration and the dose of administration of prostacyclin. So we have compared prostacyclin infusion versus inhalation in various concentrations in an animal model. Methods: Pulmonary hypertension was induced by continuous intravenous infusion of the vasoconstrictor U46619 and prostacyclin solutions of 10, 50, 100, 200 mcg/ml were inhaled using a jet nebulizer. Prostacyclin infusion was done at a rate of 100, 200, 400 ng/kg/min. Results: With inhalation of 10, 50, 100, 200 mcg/ml prostacyclin, PVR fell to values of 85%, 76%, 64%, 55% of the preinhalation value and SVR fell to values of 94%, 80%, 76%, 64% of the preinhalation value, respectively(p<0.05). PVR/SVR ratios decreased significantly in all inhalation doses(p<0.05). With infusion prostacyclin at a rate of 100, 200, 400 ng/kg/min, PVR fell to values of 73%, 60%, 50% of the preinfusion value and SVR fell to values of 68%, 54%, 38% of the preinfusion value, respectively(p<0.05). PVR/SVR ratios increased at an infusion rate of 400 ng/kg/min. Conclusion: Prostacyclin inhalation did not result in selective pulmonary vasodilation without causing any efects on the systemic vascular bed(absolute pulmonary selectivity). But it did cause more predominant vasodilation on the pulmonary vascular bed(relative pulmonary selectivity). By contrast, prostacyclin infusion caused more predominant vasodilation on the systemic vascular bed, creating the risk of severe systemic hypotension. (Korean J Anesthesiol 1998; 35: 413∼422)